Catalyst Brief

← Calendar

Readoutin 104d

Madrigal Pharmaceuticals, Inc. — Resmetirom

Phase 3 primary completion: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE).

Date
Mar 2027
Type
Readout
Indication
Non-Alcoholic Fatty Liver Disease

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Madrigal Pharmaceuticals, Inc.

  1. Dec2026